Clinical Trial Update: Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI [NA]

View source ↗

Summary

A clinical trial is evaluating whether low-dose cyclophosphamide or a calcineurin inhibitor can prevent acute graft-versus-host disease after donor lymphocyte i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Calcineurin inhibitor (e.g., tacrolimus or cyclosporine) (calcineurin inhibitor)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Graft-versus-host Disease | NA | Status: NOT_YET_RECRUITING